Alphamab Oncology (HKG:9966) obtained approval to begin a phase III clinical study of JSKN033 from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
Shares of the company were up nearly 6% in Tuesday afternoon trading.
The drug will be tested as monotherapy in patients with recurrent or metastatic cervical cancer.